Hot Investor Mandate: VC Firm Invests in USA-Based Medical Device & Diagnostics Companies With Validated PoC

29 Feb

A Venture Capital firm is currently investing out of their fourth fund. The firm looks to make early-stage investments, typically in Series A companies. Investments range from $1M to $1.5M in the initial round with up to $3M in reserve for follow on financings. The firm invests across the United States. The firm prefers to syndicate rounds with additional strong institutional investors, and is willing to serve as lead investor. 
 
The firm invests solely in early-stage medical device and diagnostics companies. The firm generally looks for companies that have created an early working prototype or obtained a proof-of-concept with supporting data. 
 
The firm seeks privately-held companies and maintains positive and productive working relationships with its portfolio companies, providing proactive assistance. The firm is more open to taking significant scientific and technical risk as opposed to sales and marketing challenges, preferring its investment to fund clinical trials and regulatory approval. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

Hot Investor Mandate: Venture Fund Seeks Healthcare Technology Companies Targeting the US Market from Pre-Seed to Series A Rounds

29 Feb

A venture fund based in the US invests in healthcare technology companies with a focus on healthcare infrastructure and enterprise solutions. The firm is currently investing out of its second, $50M fund, investing $1-2M (initially) in pre-seed to Series A companies. The firm will invest in companies that have a complete product and early customer traction. The firm will invest in companies based in the US or Canada, but when investing in Canada, the firm is focused on companies that are either targeting or entering the US market. 
 
The firm invests only in healthcare technology companies, with a focus on healthcare infrastructure solutions and enterprise software. This can include B2B healthcare solutions for providers, life sciences, and payers. Prior investments run the gamut from payment and credit tech, data structure and architecture, security, to next-gen patient acquisition tech. 
 
The firm generally will lead seed investments, and will sometimes co-lead or co-invest in Series A investments. Generally, the firm takes a board seat after investing. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

Hot Investor Mandate: VC With US & China Offices Looks for Novel Therapeutics, Medtech, Digital Health, Capable of Investing Over $10M

29 Feb

A venture capital firm based in China and US manages about USD about 4 billion in committed capital with multiple USD and RMB funds. The firm typically invests in series A and B rounds; The firm can invest anywhere from a few million $ to tens of million $ over a 10 year horizon. At present, the firm is looking for new investment opportunities in US and greater China with excellent platform for long term growth. 
 
The firm seeks to invest in a broad array of technologies including therapeutics, MedTech, digital Health and etc. Within therapeutics, the firm is interested in innovative drugs and novel biotechnology based therapies. Within MedTech, the firm is interested in a great range of platforms that address large unmet medical need globally. The firm is opportunistic in terms of subsectors and stage of development. Historically, the firm invested in immuno-oncology drugs, CNS drugs, gene therapy and gene editing, digital health and AI-backed diagnostics, radiology imaging, clinical cell and molecular genetics testing, POC devices, diagnostics and genomics, and so on. 
 
The firm is looking for competent and experienced management teams. The firm typically seeks a board seat in its portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

How to Meet Alabama Life Sci Startups at RESI South?

27 Feb

By Erika Wu, Business Development Manager, Global Tech Hubs, LSN

EW: Please introduce us to Bio Alabama. Such as mission statement and brief overview of the services offered. 

BIO Alabama Logo (1)

BIO Alabama is the leading advocate for Alabama’s bioeconomy. We represent the state on a national and international stage, promoting the intellectual and innovative capital that make our state a premier place to invest, start, and grow in bioscience.  

We represent Alabama’s bio related industries, research scientists, clinicians and business professionals who are working together to foster, develop and support the life sciences in Alabama. BIO Alabama is the state affiliate in Alabama of the Biotechnology Innovation Organization (BIO), the preeminent national association for biotechnology companies.  

Our mission is to promote biotechnology innovation by creating a favorable scientific, business and legislative environment that will facilitate the growth of emerging and existing companies while attracting new biotechnology opportunities to Alabama and to increase public awareness regarding the potential impact on quality-of-life and the state’s economy. 

EW: Please introduce us to the # startups that are presenting at RESI South in Atlanta on March 25th: 

1: Gulf SterilizationMichelle Scott – President and CEO of Gulf Sterilization

GS, F, Logo_Horizontal, RoyalBG (1)Gulf Sterilization, offers an environmentally conscious sterilizationoption to the life sciences and advanced manufacturing industries viacutting edge gaseous chlorine dioxide. This technology, developed byan offshoot of Johnson and Johnson, is provided in a state of the art,5400 square foot facility housing multiple chambers for sustainablesterilization services. In December, Gulf Sterilization wasrecommended for ISO:13485 certification ensuring the highest qualityand regulatory compliance. Recently, they accepted one of only 75invitations extended worldwide to the Global Industry ScientificExchange on Alternative Sterilization held in Munich, Germany. Activein the Association for the Advancement of Medical Instrumentation(AAMI), Gulf Sterilization also values the opportunity to foster regionalgrowth in the life science ecosystem through their membership inFMMC and Bio Alabama. 

2: ResBiotic Vivek Lal – CEO

HorizontalGreenResBResBiotic is a Biotech CPG Company based in Birmingham, AL. ResBiotic stands for Restoration Biotics where we make a new class of wellness supplements – ones that are actually science backed. Physician-developed, with your health in mind, our supplements designed to restore your microbiome and foster whole body wellness and resilience. With multiple product lines, ResBiotic® offers supplements for every body. Our hero seeks to improve symptoms, like low energy or breathing challenges and understands the value of investing in supplements to support healing or general well-being. They most value proactive, holistic, and science-backed wellness approaches to gut, lung, and immune health.

3: SynVivo Inc – Gwen Fewell – President and CEO

SynVivo-Logo-Final-NEWSynVivo Inc. is a commercial stage Organ-on-Chip company in the Life Sciences Research Tools market. Our patented platform offers 3D Tissue and Organ-on-Chip models for Neuroscience,Oncology, Inflammation, and Toxicology drug development and personalized medicine applications. The company’s vision is to  establish a new standard of predictive tools for understanding human responses in drug development, bridging the gap between pre-clinical drug testing and human clinical trials towards transformative advancements in personalizedmedicine. SynVivo’s microfluidic platform allows accurate modeling of both the morphology of human tissues and organs and the physiology of blood flow and shear stress to create more predictive models for preclinical testing of drugs. Complex in vivo microvascular environment including scale, morphology, hemodynamics of blood flow and cellular architecture are re-created invitro. SynVivo’s Organ-on Chip models feature a side-by-side architecture enabling real-time visualization and quantitation using standard analytical instrumentation.

4: Chonex – Michael Lynch – President and CEO

Logo PNG_dark colors (2)  Chonex is at the forefront of regenerative agriculture innovation with StrongSoil, a transformative product designed to rebuild and regenerate topsoil. This allows farmers to achieve higher profitability through reduced chemical use and increased crop yields. Priced to enable cost-effective implementation, StrongSoil enhances soil microbiology, thus promoting profitable farming with less risk from external threats like droughts and diseases. Comprising a comprehensive mix of beneficial microorganisms, micronutrients, and enzymes, StrongSoil is proven to significantly boost soil health and plant resilience. With five years of comprehensive research behind it, StrongSoil’s innovation is packaged in a user-friendly, water-soluble format compatible with almost all agricultural fertilizers and chemicals, marking a significant milestone in the advancement of sustainable farming.

EW: What are your initiatives and strategic goals in 2024 for Bio Alabama? 

BIO Alabama has three strategic growth pillars that include economic development, workforce initiatives and connectivity life science efforts across the state.   In 2024, BIO Alabama is offering a couple of new services to our members to support our growth pillars.   The first is an M&A assessment methodology that Dr. Blanks has used previously during his decade of work in private equity.   The goal of this assessment is to identify weaknesses in company plans, strategies, IP, financial plan, capex, etc and correct those weaknesses in order to improve the value of the company’s equity when they go in front of investors.   The second is to support SBIR/STTR applications for members through a review process to catch mistakes or missed steps in the application process.   The goal of this effort on grant applications is to increase the number of applicants that receive a full review of the scientific value of the application.   Both of these services are offered at no direct cost to our members. 

For any questions, please reach out to  Erika Wu,at e.wu@lifesciencenation.com

RESI-South-2024_02062024.

Register-now-button-new

RESI-SPAIN-1100

Hot Investor Mandate: VC Firm Invests $5-10M in Early-Stage Drug Discovery Companies Across the Globe, Open to All Modalities and Indications

22 Feb

A venture capital firm acts as a drug discovery copilot and seed investor. The firm has a unique copiloting model where they can help founders stay incredibly lean while generating the preclinical data package necessary for a high-quality Series A. The firm invests in therapeutics companies at the Seed stage and what may sometimes look like a Series A round with typical check sizes ranging from $5-10M USD. The firm can be first or second money in and is geography-agnostic. 
 
The firm solely invests in therapeutics and is modality- and indication-agnostic. Companies can be single asset or platform focused. The firm can fund anything from a well-defined “idea on paper” to existing companies with significant proof of concept data. 
 
The firm does not have specific management team requirements. The firm acts as a lead investor and typically does not take a controlling position but requests a right to take a board seat if applicable. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com

Hot Investor Mandate: Canada-Based Firm Invests in Seed to Series B Digital Health Technologies and Medtech Companies With Digital Component 

22 Feb

A venture capital firm with offices in Canada is primarily interested in investing in companies in the digital health sector but will also consider medical and diagnostic devices that have a significant digital component to them. Esplanade is looking to participate in the Seed to Series B financings of early-stage companies with typical investments between USD $0.5M-2.5M. The firm is currently operating out of its second fund in which it has made five investments after making thirteen investments out of its inaugural fund. Esplanade participates in equity investments including SAFEs and convertible notes. The firm invests primarily in companies based in Canada, the United States, Europe, and Israel. 
 
The firm is primarily interested in investing in companies in the digital health sector but will also consider medical and diagnostic devices that have a significant digital component to them. The firm is open to all modalities within digital health but requires that the technologies be patient facing or have a patient component. The firm will not consider investments in biotech or pharma but will consider digital therapeutics. The firm is phase agnostic and will invest in developing as well as on the market technologies. The firm will only invest in Class I and Class II (510k) medical devices, avoiding Class III (PMA). The firm is disease agnostic and will consider companies across all indications but prefers that there is ample market size for the technology. 
 
The firm prefers to work with experienced management teams. The firm looks to invest in companies in which the founder has a significant stake in the business. The firm is an active and strategic investor and will take a board seat or board observer role as determined by check size on a case-by-case basis. The firm will participate both as lead and co-investor. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com

Hot Investor Mandate: Life Sciences & Healthcare-Focused VC Invests in Seed Stage Companies in Devices, Diagnostics, and Digital Health

22 Feb

Based in the US, a venture capital firm invests in early-stage life sciences and healthcare. The firm seeks early-stage investment opportunities from seed to series A, generally investing $50k to $1.5M in the initial round, with potential for follow-on investments up to $3M. The firm is focused regionally based companies (those close to their office) but also seek opportunities globally. The firm is open to both leading and co-investing. 
 
The firm invests in medical devices, diagnostics and digital health. The firm is open to considering all subsectors and indications. 
 
While the firm can invest in companies based elsewhere under certain circumstances, the firm is primarily focused on companies in the same state. The firm is active in supporting their portfolio companies and will consider taking a board seat on a case-by-case basis. Additionally, the firm is open to engages with entrepreneurs and founders at a very early stage. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com